Clinical Trials for GIST

3 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TherapeuticVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
TherapeuticVICCPHI0958
02/05/2010
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology
Screen, Detect, DiagnoseVICCMD1286
12/17/2012
Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib

You do not have JavaScript enabled. This site works better with JavaScript turned on.